BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12441811)

  • 1. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma.
    Esdaile B; Davis M; Portsmouth S; Sarker D; Nelson M; Gazzard B; Bower M
    AIDS; 2002 Nov; 16(17):2344-7. PubMed ID: 12441811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
    Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
    Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD003256. PubMed ID: 25221796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
    Martin-Carbonero L; Barrios A; Saballs P; Sirera G; Santos J; Palacios R; Valencia ME; Alegre M; Podzamczer D; González-Lahoz J;
    AIDS; 2004 Aug; 18(12):1737-40. PubMed ID: 15280789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS).
    Bendle M; Pealing J; Papanastasopoulos P; Bower M
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):611-5. PubMed ID: 25055936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
    Loke WC; Spittle MF; Mitchell S; Kulasegaram R
    Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
    Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
    AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
    Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
    AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.
    Nguyen HQ; Magaret AS; Kitahata MM; Van Rompaey SE; Wald A; Casper C
    AIDS; 2008 May; 22(8):937-45. PubMed ID: 18453853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
    Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
    J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does HAART lead to the resolution of Kaposi's sarcoma?
    Stebbing J; Portsmouth S; Gazzard B
    J Antimicrob Chemother; 2003 May; 51(5):1095-8. PubMed ID: 12668573
    [No Abstract]   [Full Text] [Related]  

  • 13. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of highly active antiretroviral therapy on the evolution of AIDS-associated Kaposi's sarcoma].
    Mercè Alsina M ; Bulla F; Conill C; Mallolas J; Bernardo Pérez-Cuevas J ; Lecha M
    Med Clin (Barc); 2000 Dec; 115(19):736-7. PubMed ID: 11141440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group.
    Núñez M; Machuca A; Soriano V; Podzamczer D; González-Lahoz J
    AIDS; 2000 May; 14(8):913-9. PubMed ID: 10853972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of endogenous interferon-alpha and human herpesvirus 8 in HIV-infected patients with Kaposi's sarcoma.
    Plettenberg A; Albrecht D; Lorenzen T; Meyer T; Arndt R; Stoehr A
    Eur J Med Res; 2002 Jan; 7(1):19-24. PubMed ID: 11827836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of HIV-related Kaposi's sarcoma].
    Reyners AK; Sprenger HG; Suurmeijer AJ; van der Graaf WT
    Ned Tijdschr Geneeskd; 2006 Mar; 150(11):589-93. PubMed ID: 16610494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
    Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
    Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin.
    Lucia MB; Rutella S; Leone G; Larocca LM; Vella S; Cauda R
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):369-78. PubMed ID: 12138343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.